Steven DellaRocca

795 total citations
12 papers, 629 citations indexed

About

Steven DellaRocca is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Steven DellaRocca has authored 12 papers receiving a total of 629 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 3 papers in Oncology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Steven DellaRocca's work include Histone Deacetylase Inhibitors Research (8 papers), Protein Degradation and Inhibitors (8 papers) and Ubiquitin and proteasome pathways (3 papers). Steven DellaRocca is often cited by papers focused on Histone Deacetylase Inhibitors Research (8 papers), Protein Degradation and Inhibitors (8 papers) and Ubiquitin and proteasome pathways (3 papers). Steven DellaRocca collaborates with scholars based in United States. Steven DellaRocca's co-authors include Guang-Xin Xu, Maria Samson, Ruzanna Atoyan, Changgeng Qian, Xiong Cai, Cheng-Jung Lai, Brian Zifcak, Da-Gong Wang, Ling Yin and Hui Qu and has published in prestigious journals such as Blood, Cancer Research and Clinical Cancer Research.

In The Last Decade

Steven DellaRocca

12 papers receiving 614 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Steven DellaRocca United States 7 515 177 89 55 53 12 629
Hai-Xiao Zhai 5 582 1.1× 222 1.3× 162 1.8× 71 1.3× 38 0.7× 6 717
Lindsay Stimson United Kingdom 11 870 1.7× 216 1.2× 96 1.1× 48 0.9× 50 0.9× 13 1.0k
Liv Johannessen United States 8 241 0.5× 152 0.9× 42 0.5× 57 1.0× 30 0.6× 19 374
Mylissa Borek United States 5 299 0.6× 109 0.6× 46 0.5× 35 0.6× 44 0.8× 10 367
Ann Katrin Greifenberg Germany 7 641 1.2× 267 1.5× 48 0.5× 102 1.9× 33 0.6× 8 762
Candice L. Horn United States 6 457 0.9× 251 1.4× 39 0.4× 55 1.0× 45 0.8× 10 552
Samar Alanazi United States 8 347 0.7× 271 1.5× 51 0.6× 102 1.9× 46 0.9× 13 575
Barbara Hibner United States 6 391 0.8× 223 1.3× 33 0.4× 64 1.2× 68 1.3× 11 519
Steve W. Elmore United States 3 369 0.7× 179 1.0× 32 0.4× 25 0.5× 40 0.8× 4 437
Michelle S. Miller United States 12 284 0.6× 149 0.8× 54 0.6× 49 0.9× 14 0.3× 27 517

Countries citing papers authored by Steven DellaRocca

Since Specialization
Citations

This map shows the geographic impact of Steven DellaRocca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven DellaRocca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven DellaRocca more than expected).

Fields of papers citing papers by Steven DellaRocca

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven DellaRocca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven DellaRocca. The network helps show where Steven DellaRocca may publish in the future.

Co-authorship network of co-authors of Steven DellaRocca

This figure shows the co-authorship network connecting the top 25 collaborators of Steven DellaRocca. A scholar is included among the top collaborators of Steven DellaRocca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven DellaRocca. Steven DellaRocca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Booher, Robert N., Grzegorz S. Nowakowski, Krish Patel, et al.. (2018). Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination with Targeted Therapies and Preliminary Phase 1 Clinical Results in Non-Hodgkin Lymphoma. Blood. 132(Supplement 1). 4168–4168. 7 indexed citations
2.
Sun, Kaiming, Ruzanna Atoyan, Mylissa Borek, et al.. (2016). Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers. Molecular Cancer Therapeutics. 16(2). 285–299. 109 indexed citations
3.
Sun, Kaiming, Ruzanna Atoyan, Mylissa Borek, et al.. (2016). The Combination of Venetoclax and CUDC-907 Exhibits Synergistic Activity in Venetoclax-Refractory DLBCL. Blood. 128(22). 4184–4184. 4 indexed citations
4.
Atoyan, Ruzanna, Maria Samson, Anna Walaszczyk, et al.. (2014). Abstract 917: Post-treatment changes in levels of TNF family ligands and XIAP may predict sensitivity to IAP antagonist CUDC-427. Cancer Research. 74(19_Supplement). 917–917. 1 indexed citations
5.
Wojakowska, Anna, Ruzanna Atoyan, Anas Younes, et al.. (2014). Abstract 1879: Dual function HDAC and PI3K inhibitor, CUDC-907 affects cancer cells and the tumor microenvironment in hematological malignancies. Cancer Research. 74(19_Supplement). 1879–1879. 2 indexed citations
6.
Wang, Jing, Anna Ma, Ruzanna Atoyan, et al.. (2013). CUDC-907, a Dual HDAC and PI3K Inhibitor, Potentially Targets Cancer Cells and The Microenvironment In Hematological Malignancies. Blood. 122(21). 4930–4930. 2 indexed citations
7.
Qian, Changgeng, Cheng-Jung Lai, Rudi Bao, et al.. (2012). Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling. Clinical Cancer Research. 18(15). 4104–4113. 188 indexed citations
8.
Wang, Da-Gong, Hui Qu, Ling Yin, et al.. (2012). Abstract 3744: Antitumor activity of CUDC-907, a dual PI3K and HDAC inhibitor, in hematological cancer models. Cancer Research. 72(8_Supplement). 3744–3744. 6 indexed citations
9.
Bao, Rudi, Da-Gong Wang, Hui Qu, et al.. (2011). Abstract 2615: Antitumor activity of a dual PI3K and HDAC inhibitor in hematologic cancer models. Cancer Research. 71(8_Supplement). 2615–2615. 1 indexed citations
10.
11.
Bao, Rudi, Cheng-Jung Lai, Hui Qu, et al.. (2009). CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy. Clinical Cancer Research. 15(12). 4046–4057. 80 indexed citations
12.
Bao, Rudi, Cheng-Jung Lai, Da-Gong Wang, et al.. (2009). Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non–small cell lung cancer. Molecular Cancer Therapeutics. 8(12). 3296–3306. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hai-Xiao Zhai Breakdown of academic impact, for papers by Lindsay Stimson Breakdown of academic impact, for papers by Liv Johannessen Breakdown of academic impact, for papers by Mylissa Borek Breakdown of academic impact, for papers by Ann Katrin Greifenberg Breakdown of academic impact, for papers by Candice L. Horn Breakdown of academic impact, for papers by Samar Alanazi Breakdown of academic impact, for papers by Barbara Hibner Breakdown of academic impact, for papers by Steve W. Elmore Breakdown of academic impact, for papers by Michelle S. Miller
Rankless by CCL
2026